GlassScriptPhysician profile
Alan S Curtis
NPI 1952369894
$184,447.59
in general payments reported to CMS, 2019-2025
22 companies · $5,640 in 2025
The $5,640 reported for 2025 was more than what 83% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,023 · 2020: $58K · 2021: $639 · 2022: $7,927 · 2023: $101K · 2024: $7,855 · 2025: $5,640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $99K · Consulting Fee: $11K · Food and Beverage: $2,701 · Travel and Lodging: $1,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $99,083.02 |
| Consulting Fee | $11,398.75 |
| Food and Beverage | $2,700.60 |
| Travel and Lodging | $1,380.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $99,328.70 | 2021-2025 | Tapestry |
| Anika Therapeutics, INC. | $64,525.27 | 2020-2022 | |
| Arthrex, INC. | $12,392.99 | 2020-2025 | Arthrex |
| Depuy Synthes Products, INC. | $4,282.72 | 2019-2023 | |
| Kairos Surgical INC | $1,156.10 | 2023-2024 | |
| Stryker Corporation | $973.94 | 2021-2024 | Inspace, Na |
| Smith+Nephew, INC. | $548.25 | 2019-2024 | Na, N/A, Bioinductive Implant With Arthroscopic Delivery System - Medium |
| Exactech, INC. | $306.46 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $286.19 | 2021-2025 | Zilretta, Iovera, Exparel |
| Osteoremedies, LLC | $170.66 | 2025 | Remedy Spacer, Osteoboost Select 5cc, Biowash Surgical Irrigation |
| Orthofix Medical, INC. | $131.77 | 2023 | Physio-Stim |
| Aesculap Biologics, LLC | $108.90 | 2021 | |
| Bioventus LLC | $52.21 | 2021-2023 | Exogen Ultrasound Bone Healing System |
| Depuy Synthes Sales INC. | $43.21 | 2024 | Orthovisc, Monovisc |
| Pacira Therapeutics, INC. | $32.14 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $29.42 | 2024 | |
| Access Pro Medical, LLC | $24.98 | 2025 | Matriderm |
| Pfizer INC. | $23.32 | 2024 | |
| Ferring Pharmaceuticals INC. | $17.00 | 2019 | |
| Electronic Waveform Lab, INC. | $13.36 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$606,800.14 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Curtis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.